Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are both types of non-Hodgkin lymphoma that affect the lymphocytes, a type of white blood cell. Both cancers are so similar that ...

Zanubrutinib demonstrated a 5-year progression-free survival (PFS) rate of 72.2% and overall survival rate of 85.1% in patients with deletion of the 17p chromosome (del[17p]) chronic lymphocytic ...

Forbes contributors publish independent expert analyses and insights. Joan Vos MacDonald is a New York-based writer who covers Korean media. Jun 17, 2022, 08:14am EDT This article is more than 3 years ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

SLL, also known as Studio LuluLala, announced a brand-new list of releases slated for the second half of the year and picked "popular appeal" as the keyword for its content in a press event Thursday. ...